氯法齐明
药品
医学
重症监护医学
生物
药理学
免疫学
麻风病
作者
Niccolò Riccardi,Andrea Giacomelli,Diana Canetti,Agnese Comelli,Enrica Intini,Giovanni Gaiera,Mama Moussa Diaw,Zarir Udwadia,Giorgio Besozzi,Luigi Ruffo Codecasa,Antonio Di Biagio
出处
期刊:Future Microbiology
[Future Medicine]
日期:2020-05-01
卷期号:15 (7): 557-566
被引量:27
标识
DOI:10.2217/fmb-2019-0231
摘要
Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential in vitro mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI